Garcia-Pagan Juan Carlos, Francoz Claire, Montagnese Sara, Senzolo Marco, Mookerjee Rajeshwar P
Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Universitat de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain; Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN-Liver), Spain.
Hepatology and Liver Intensive Care Unit, Hôpital Beaujon, INSERM. Clichy; France.
J Hepatol. 2021 Jul;75 Suppl 1:S135-S146. doi: 10.1016/j.jhep.2021.01.027.
Along with a growing understanding of the pathophysiology of cirrhosis and its complications, new therapies and management strategies have emerged in recent years. Many of these advances have helped inform the current EASL clinical practice guidelines on the management of some of the key complications of cirrhosis, such as ascites, variceal bleeding and infection. However, there are still some aspects of management where the evidence base is less clear, and/or where opinions amongst practitioners remain divided. Some of these more controversial areas are explored in this section, wherein we present evidence culminating in a suggested management approach based on expert opinion and extending beyond the current guidelines.
随着对肝硬化及其并发症病理生理学的认识不断加深，近年来出现了新的治疗方法和管理策略。其中许多进展为欧洲肝脏研究学会（EASL）目前关于肝硬化一些关键并发症（如腹水、静脉曲张出血和感染）管理的临床实践指南提供了参考依据。然而，在管理的某些方面，证据基础仍不明确，和/或从业者之间的意见仍存在分歧。本节将探讨其中一些更具争议性的领域，我们在此展示相关证据，并最终基于专家意见提出一种建议的管理方法，该方法超出了当前指南的范围。
